The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome

Growth Hormone and IGF Research

Volumn 13, Issue 5, 2003, Pages 269-274

  Höybye, Charlotte ^a   Frystyk, Jan ^b   Thorén, Marja ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adults; GH; GH treatment; GHBP; IGF I; IGFBP; Obesity; PWS

Indexed keywords

GROWTH FACTOR; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; HUMAN GROWTH HORMONE; PLACEBO; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGE; ARTICLE; BEHAVIOR DISORDER; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; FEMALE; GENETIC DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS DISEASE; MALE; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT STATURE; TITRIMETRY;

EID: 0141742646     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00017-0     Document Type: Article

References (28)

1. P. Burman, E.M. Ritzén, A.C. Lindgren, Endocrine dysfunction in Prader Willi syndrome: a review with special reference to GH, Endocr. Rev. 22 (2001) 787-799.
2. V.A. Holm, S.B. Cassidy, M.G. Butler, J.M. Hanchett, L.R. Greenswag, B.Y. Whitman, F. Greenberg, Prader Willi syndrome: consensus diagnostic criteria, Pediatrics 91 (1993) 398-401.
3. C. Höybye, A. Hilding, H. Jacobsson, M. Thorén, Metabolic profile and body composition in adults with Prader Willi syndrome and severe obesity, J. Clin. Endocrinol. Metab. 87 (2002) 3590-3597.
4. S.Y. Nam, E.J. Lee, K.R. Kim, B.S. Cha, Y.D. Song, S.K. Lim, H.C. Lee, K.B. Huh, Effect of obesity on total and free insulin-like growth factor (IGF-I, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, and growth hormone, Int. Obes. Relat. Metab. Disord. 21 (1997) 355-359.
5. J. Frystyk, E. Vestbo, C. Skjærbæk, C.E. Mogensen, H. Ørskov, Free insulin-like growth factors in human obesity, Metabolism 44 (1995) 37-44.
6. J. Frystyk, C. Skjærbæk, E. Vestbo, S. Fisker, H. Ørskov, Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes, Diabetes Metab. Rev. 15 (1999) 314-322.
7. C. Höybye, A. Hilding, H. Jacobsson, M. Thorén, Growth hormone treatment improves body composition in adults with Prader Willi syndrome, Clin. Endocrinol. 58 (2003) 653-661.
8. A.C. Lindgren, U. Grandell, E.M. Ritzén, M. Anvret, Diagnosis of the Prader-Willi syndrome by proving the absence of unmethylated PW71 DNA fragment, Acta Paediatr. 85 (1996) 195-198.
9. J. Frystyk, C. Skjærbæk, B. Dinesen, H. Ørskov, Non-competitive time-resolved immunofluorometric assay for determination of human insulin-like growth factor I and II, Growth Regul. 5 (1995) 169-176.
10. J. Frystyk, C. Skjærbæk, B. Dinesen, H. Ørskov, Free insulin-like growth factors (IGF-I and IGF-II) in human serum, FEBS Lett. 348 (1994) 185-191.
11. S. Fisker, J. Frystyk, L. Skriver, E. Vestbo, K.K.Y. Ho, H. Ørskov, A simple, rapid immunometric assay for determination of functional and growth hormone (GH)-occupied GH-binding protein in human serum, Eur. J. Invest. 26 (1996) 779-785.
12. G.E. Krassas, N. Pontikides, T. Kaltsas, A. Dumas, J. Frystyk, J.W. Chen, A. Flyvbjerg, Free and total insulin-like growth factor (IGF)-I, II, and IGF-binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease, J. Clin. Endocrinol. Metab. 88 (2003) 132-135.
13. Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency:summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency, J. Clin. Endocrinol. Metab. 83 (1998) 379-395.
14. C. Skjærbæk, N. Vahl, et al., Serum free insulin-like growth factor-I in growth hormone-deficient adult before and after growth hormone replacement, Eur. J. Endocrinol. 137 (1997) 132-137.
15. R. Fernholm, M. Bramnert, E. Hagg, A. Hilding, D.J. Baylink, S. Mohan, M. Thorén, Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease, J. Clin. Endocrinol. Metab. 85 (2000) 4104-4112.
16. P.D.K. Lee, K. Hwu, H. Henson, B.T. Brown, J.T. Bricker, A.D. LeBlanc, M.L. Fioretto, F. Greenberg, W. Klish, Body composition studies in Prader-Willi syndrome (PWS): effects of growth hormone (GH) therapy, Basic Life Sci. 60 (1993) 201-206.
17. A.P. Goldstone, E.L. Thomas, A.E. Brynes, J.D. Bell, G. Frost, N. Saeed, J.V. Hajnal, J.K. Howard, A. Holland, S.R. Bloom, Visceral adipose tissue and metabolic complications of obesity are reduced in Prader Willi syndrome female adults: evidence for novel influences on body fat distribution, J. Clin. Endocrinol. Metab. 86 (2001) 4330-4338.
18. S. Söderberg, B. Ahrén, M. Eliasson, B. Dinesen, K. Brismar, T. Olsson, Circulating IGF binding protein-1 is inversely associated with leptin in non-obese men and obese postmenopausal women, Eur. J. Endocrinol. 144 (2001) 283-290.
19. W.F. Blum, N. Horn, J. Kratzsch, J.O.L. Jorgensen, A. Juul, D. Teale, K. Mohnike, M.B. Ranke, Clinical studies of IGFBP-2 by radioimmunoassay, Growth Regul. 3 (1993) 100-104.
20. C.J. Partch, C. Lammer, G. Gillessen-Kaesbach, R. Pankau, Adult patients with Prader-Willi syndrome:clinical characteristics, life circumstances and growth hormone secretion, Growth Horm. IGF Res. (Suppl.) 10 (2000) 81-85.
21. U. Eiholzer, K. Stutz, C. Weinmann, T. Torresani, L. Molinari, A. Prader, Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome, Eur. J. Pediatr. 157 (1998) 890-893.
22. S.M. Harrison, R. Barnard, K.Y. Ho, I. Rajkovic, M.J. Waters, Control of growth hormone (GH)-binding protein release from human hepatoma cells expressing full-length GH receptor, Endocrinology 136 (1995) 651-659.
23. S. Fisker, N. Vahl, T.B. Hansen, J.O.L. Jorgensen, C. Hagen, H. Ørskov, J.S. Christiansen, Growth hormone (GH) substitution for one year normalises elevated GH-binding protein levels in GH deficient adults secondary to a reduction in body fat. A placebo controlled trial, Growth Horm. IGF Res. 8 (1998) 105-112.
24. T.K. Hansen, J.O.L. Jørgensen, J.S. Christiansen, Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age, J. Clin. Endocrinol. Metab. 87 (2002) 2185-2193.
25. M.H. Rasmussen, K.K. Ho, L. Kjems, J. Hilsted, Serum growth hormone-binding protein in obesity: effect of a short term, very low calorie diet and diet-induced weight loss, J. Clin. Endocrinol. Metab. 81 (1996) 1519-1524.
26. A.M. Rosenfalck, S. Maghsoudi, S. Fisker, J.O.L. Jorgensen, J.S. Christiansen, J. Hilsted, A.A. Volund, S. Madsbad, The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults, J. Clin. Endocrinol. Metab. 85 (2000) 4173-4181.
27. W.B. Zipf, Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy, Acta Paediatr. (Suppl.) 443 (1999) 115-117.
28. W. Jeffcoate, Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence, Drug Saf. 25 (2002) 199-212.